Trial Profile
An Open Label 52-week Study to Evaluate the Safety and Efficacy of Tegaserod Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Aug 2016
Price :
$35
*
At a glance
- Drugs Tegaserod (Primary)
- Indications Constipation
- Focus Adverse reactions
- Sponsors Novartis
- 26 Apr 2012 New trial record